`ESTTA568094
`ESTTA Tracking number:
`10/30/2013
`
`Filing date:
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`Notice of Opposition
`
`Notice is hereby given that the following party opposes registration of the indicated application.
`Opposer Information
`
`Name
`Granted to Date
`of previous
`extension
`Address
`
`Novartis AG
`10/30/2013
`
`CH-4002
`Basel,
`SWITZERLAND
`
`Attorney
`information
`
`Maury M. Tepper, III
`Tepper & Eyster, PLLC
`3724 Benson Drive
`Raleigh, NC 27609
`UNITED STATES
`mtepper@teiplaw.com Phone:919-861-8903
`Applicant Information
`
`Application No
`Opposition Filing
`Date
`International
`Registration No.
`Applicant
`
`79121577
`10/30/2013
`
`1138830
`
`Publication date
`Opposition
`Period Ends
`International
`Registration Date
`
`07/02/2013
`10/30/2013
`
`09/04/2012
`
`UCB PHARMA, S.A.
`Allée de la Recherche 60
`B-1070 BRUXELLES, BEX
`BEX
`Goods/Services Affected by Opposition
`
`Class 005. First Use: 0 First Use In Commerce: 0
`All goods and services in the class are opposed, namely: Pharmaceutical preparations and
`substances for the treatment of immunology disorders, pharmaceutical preparations and substances
`for the treatment of central nervous system diseases
`
`Grounds for Opposition
`
`Priority and likelihood of confusion
`
`Trademark Act section 2(d)
`
`Mark Cited by Opposer as Basis for Opposition
`
`U.S. Application
`No.
`Registration Date
`
`85501826
`
`NONE
`
`Application Date
`
`12/22/2011
`
`Foreign Priority
`Date
`
`NONE
`
`
`
`Word Mark
`Design Mark
`
`SEEBARI
`
`Description of
`Mark
`Goods/Services
`
`NONE
`
`Class 005. First use: First Use: 0 First Use In Commerce: 0
`Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal
`preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical
`preparations acting on the central nervous system;Pharmaceutical preparations
`and substances for the treatment of gastro-intestinal diseases; Pharmaceutical
`preparationsfor the treatment and prevention of diseases and disorders of the
`autoimmune system, the metabolic system, the musculo-skeletal system and the
`genitourinary system; pharmaceutical preparations for use in hematology and in
`tissue and organ transplantation; Pharmaceutical preparations for the treatment
`of eye diseases and conditions; Pharmaceutical preparations for the treatment
`of heart rhythm disorders; Pharmaceutical preparations for the treatment of
`immune system related diseases and disorders; Pharmaceutical preparations for
`the treatment of kidney diseases; Pharmaceutical preparations fortreating
`diabetes; Pharmaceutical preparations for use in dermatology; Pharmaceutical
`products for ophthalmological use; Pharmaceutical products for the prevention
`and treatment of cancer; Pharmaceutical products for the treatment of bone
`diseases; Pharmaceutical products for treating respiratory diseases;
`Pharmaceutical products for treating respiratory diseases and asthma;
`Pharmaceuticals, namely, anti-infectives
`
`Attachments
`
`85501826#TMSN.jpeg( bytes )
`SENBARI Notice of Opposition.pdf(1603462 bytes )
`
`Certificate of Service
`
`The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address
`record by First Class Mail on this date.
`
`Signature
`Name
`Date
`
`/Maury M. Tepper, III/
`Maury M. Tepper, III
`10/30/2013
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`In the matter of Trademark Application Serial No. 79/ I 2|.S77
`Filed September 4. 2012
`For the Mark SENBARI
`
`Opposition No.
`
`) )
`
`) )
`
`)
`
`) )
`
`) )
`
`)
`
`Novartis AG,
`
`Opposer.
`
`v.
`
`ll('l5 Pl l:\RMA. 5..-\...
`
`Applicant.
`
`NOTICE OF‘ OPPOSITION
`
`Opposer Novartis AG, CH-4002. Basil. Switzerland. believes that
`
`it will be
`
`damaged by registration of the mark shown in Application Serial No. 79/ 121.577. and
`
`hereby opposes the same.
`
`The grounds for opposition are as follows:
`
`I.
`
`Applicant filed Application Serial No. 79/ 121.577 on or about September 4. 20l2
`
`to register the mark SENBARI in connection with “l’harmaceutical pl'cpat'a1itms and
`
`.~uh.~:tanccs for the treatment of l|1lI1'IUI10lugy disorders. plmrmaccuticztl preparations and
`
`sttbslztriccs liar the treatment ol'cenlrzt| iiewmts s_\:.s'tctI1 discziscs” in Class 5 ("Applicant's
`
`Mark").
`
`2.
`
`Opposer will be damaged by the registration ol'Applicant's Mark.
`
`
`
`Notice of Opposition
`Serial No. 79/ I 2 I .577
`
`Page 2
`
`3.
`
`Opposer is the owner of United States Trademark Application No. 85/50l.826 for
`
`the mark SEEBARI. filed on December 22. 20l l. for "Anti-intlamntatories: Atttihztctcrial
`
`pltannaecuticaIs:
`
`.=~\ntihintics:
`
`.«'\ntil'ungal
`
`prcparatinn.s‘: Antit-irttlsz
`
`(.'at\liuvascttlur
`
`plmnnaeeuticals: Pltarmaccutical preparatiuns acting on the central ncrmus S_\‘$li:IIl2
`
`l’l1at'm:tceutieal preparations and substances for the treatment oi’gusttwititestinal diseztses:
`
`l’harmaccutical pI'cp:Il'iIll0ltS fur the treatment and prevention of diseases and Lll.\‘Ul'(lL'l'S iii‘
`
`the autoimmune systetn.
`
`the metabolic .~;_\-stem.
`
`the mttseulu-.slsclct:t| $_\‘.\'lt.‘ln and the
`
`-_.»enituurinary systetn: pharmaceutical preparations for use in hematolu«-_\= and in tissue and
`
`organ transplantation; l’ltarmaecuticaI preparatimis fur the treatment ul'e_\'e disca.-;c.~. and
`
`conditions;
`
`l’ltat'macetttical preparations for the treatment oi‘ heart rhythm LllSul'LlCI'S:
`
`l’lmi-maceutical preparatitms for the treatment ul‘ immune S}'Slcl‘l1 related diseases and
`
`tlismders:
`
`Pharmaceutical
`
`preparations
`
`for
`
`the
`
`treatment
`
`oi‘
`
`kitlne_\‘
`
`cliseztses:
`
`l’lturmaceutical preparations for treating diabetes: l’liarmaeeuticul pt'epat'ations fur use in
`
`tlermatnlng}: l’hartnaeeutical products for opllthalmulogical use; Pll:ll‘tIt;lL".cllllCill prmlttets
`
`fur the prcx-entiott and treatment ul‘ cancer: l’l1armacculical prntlucts fur the treatment of
`
`bone LllSCit3L‘SZ Pharmaceutical products for treating respiratur_\
`
`l.ll$Cil>C5l l’|iarmaceutical
`
`products for treating rc:~;pirator_\-'
`
`tliseztses and astluna;
`
`l’ltztrntucettticals. name-l_\. unti-
`
`ittlccti\'cs" (“Opposer’s Mark").
`
`4.
`
`The filing date for Opposer's Mark (December 22. 20l l) is prior to any priority
`
`date that Applicant can claim relating to Applicant‘s Mark.
`
`3.
`
`A licant’s Mark so resembles 0
`PP
`
`PP0
`
`ser’s Mark as to be likel
`
`Y
`
`to cause confusion _
`
`or to cause mistake or to deceive.
`
`IQ
`
`
`
`Notice of Opposition
`Serial No. 79/ l2l.577
`Page 3
`
`WHEREFORE. Opposer prays that said application Serial No. 79/121577. be
`
`rejected. that no registration be issued. and that this Opposition be sustained in favor of
`
`Opposer.
`
`This the 30"‘ day of October. 2013.
`
`
`
`s mitted.
`Respectfully
`
`
`
`
`ury M.
`e/pper, I ll
`
`Kathryn M. Eystcr
`Tepper & Eyster. PLLC
`(919) 86 l -8901 telephone
`(919) 861-8913 lelefax
`mtepQCt‘!(i'.lCi|)la\V.C()t1]
`
`Attorneys for Opposer
`
`
`
`Notice of Opposition
`Serial No. 79/I2 L577
`Page 4
`
`CERTIFICATE OF FILING
`
`I do hereby certify that on October 30, 2013. I filed via electronic means
`
`(ESTTA) this NOTICE OF OPPOSITION with the:
`
`U. S. Patent and Trademark Office
`Trademark Trial and Appeal Board
`P.O. Box 1451
`
`Alexandria, Virginia 22313-1451
`
`With a copy via First Class mail:
`
`Chrislnplicr S. Adkins
`Wcndcruth. Lind &. P0lI«'.lCI\. l,.L.l’.. Ste 400 [i
`103!) 15th SI NW
`
`Washington. Dislricl ( )l‘('nlumhiu 20005
`
`J‘ . 949$/¢z"wb
`
`;r(
`
`
`/ hompson. Pa‘ alegal
`
`
`
`..